EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary purpose is to determine the changes in gene expression induced by IFNb-1a (Rebif) and atorvastatin (Lipitor) combination therapy in patients with an isolated clinical syndrome suggestive of multiple sclerosis (MS), to identify markers of therapeutic response, and to predict patients' clinical response based on their in vitro response to this combination therapy measured by the gene expression levels in activated peripheral blood mononuclear cells (PBMCs).
| Condition | Intervention |
|---|---|
|
Multiple Sclerosis |
Drug: Rebif |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) |
| Official Title: | EARLY IFNb-1a (Rebif) and Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis |
- To determine the effects of IFNb-1a plus atorvastatin versus IFNb-1a plus placebo on the gene expression in peripheral blood mononuclear cells (PBMCs) derived from patients with isolated clinical syndrome suggestive of MS [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- To identify markers of therapeutic response and to predict patients' clinical response based on their in vitro response to this combination therapy measured by the gene expression levels in activated PBMCs [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- evaluate safety and efficacy of combination therapy with Rebif and Lipitor in patients with clinicayy isolated syndrome suggestive of MS. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 30 |
| Study Start Date: | October 2004 |
| Study Completion Date: | October 2008 |
| Primary Completion Date: | October 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Rebif + Lipitor |
Drug: Rebif
Rebif 44mcg TIW
|
Detailed Description:
Multiple Sclerosis (MS) is a chronic neurologic disease, characterized pathologically by focal areas of inflammation, demyelination, axonal injury and degeneration in the central nervous system. MS follows several different disease courses. Approximately, 90% of patients have a relapsing form of the disease. We propose that atorvastatin (Lipitor) may enhance the immunomodulatory effects of INFb-1a (Rebif) in patients with clinically isolated neurological syndrome suggestive of MS. This combination may be more effective in preventing development of definitive relapsing-remitting MS if administered early in the course of the disease. The study will identify markers of disease activity that are selectively affected by this combination therapy. Identified markers may be used in future clinical trials to predict patient's clinical response and to monitor the response to treatment as a secondary outcome measure.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with isolated clinical syndrome suggestive of MS
At least three out of four magnetic resonance imaging (MRI) findings on the initial scan:
- One Gd-enhancing lesion or nine T2 hyperintense lesions;
- At least one infratentorial lesion;
- At least one juxtacortical lesion; and
- At least three periventricular lesions.
- Expanded Disability Status Scale (EDSS) 0-5.5
- 18 to 60 years of age
- At least one relapse in previous 12 months
Exclusion Criteria:
- Patients with a diagnosis of clinically definitive relapsing-remitting (RR) MS, secondary progressive, or primary progressive MS.
- Patients who have ever been treated with mitoxantrone, cytoxan, cyclophosphamide, or total lymphoid irradiation (TLI).
- Patients treated with IFNb-1a, IFNb-1b, glatiramer acetate, intravenous immunoglobulins (IVIg), plasma exchange, methotrexate, or azathioprine in the previous 3 months.
- Patients treated with intravenous or oral steroids within 30 days prior to baseline MRI.
- Patients who have been treated with statins in the previous 3 months.
- Pregnant or breast-feeding women.
- Patients with a history of severe cardiac, hepatic, pulmonary, gastrointestinal, or renal disease.
- Abnormal baseline blood tests including alanine transaminase (ALT) or aspartate transaminase (AST) greater than twice the upper limit of normal
Contacts and Locations| United States, North Carolina | |
| University of North Carolina-Chapel Hill MS Clinic Within the Neuroscience Hospital | |
| Chapel Hill, North Carolina, United States, 27599 | |
| Principal Investigator: | Silva Markovic-Plese | University of North Carolina, Chapel Hill |
More Information
No publications provided
| Responsible Party: | Silva Markovic-Plese, UNC Chapel Hill |
| ClinicalTrials.gov Identifier: | NCT00137176 History of Changes |
| Other Study ID Numbers: | 04-NEUR-293 |
| Study First Received: | August 26, 2005 |
| Last Updated: | June 22, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of North Carolina, Chapel Hill:
|
Clinically Isolated Syndrome |
Additional relevant MeSH terms:
|
Multiple Sclerosis Sclerosis Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases Pathologic Processes Atorvastatin Interferon beta 1a Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Enzyme Inhibitors Lipid Regulating Agents Therapeutic Uses Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents |
ClinicalTrials.gov processed this record on May 23, 2013